2.90 0.15 (5.45%)

74.61% Fall from 52W High

184.6K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Inotiv Inc Key Metrics

Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
11.1 / 100
Expensive Valuation
29.0 / 100
Technically Neutral
55.4 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

Inotiv Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Sep '22Sep '23Sep '24Sep '25Sep '26450500550600Actual RevenueAvg. Estimate
Hit

Inotiv Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-4.2
Avg. Estimate
-2.4
Low Estimate
-2.5
High Estimate
-2.4
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 41.8% in FY25

Consensus Recommendation

3 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Hold2Strong Buy

The consensus recommendation from 3 analysts for Inotiv Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Inotiv Inc Stock Analysis

Inotiv Inc stock analysis with key metrics, changes, and trends.

Inotiv Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$490.74 M14.27%negative

Annual Revenue fell 14.27%, in the last year to $490.74 M. Its sector's average revenue growth for the last fiscal year was 1.02%.

Annual Net Profit$108.44 M3.14%negative

Annual Net Profit fell 3.14% in the last year to $108.44 M. Its sector's average net profit growth for the last fiscal year was -16.93%.

Price to Earning Ratio-0.81-negative

Price to Earning Ratio is -0.81, which is negative.

Stock Price$2.90-72.74%negative

Stock Price fell 72.74% and underperformed its sector by 83.63% in the past year.

Quarterly Revenue$119.88 M11.53%negative

Quarterly Revenue fell 11.53% YoY to $119.88 M. Its sector's average revenue growth YoY for the quarter was 3.89%.

Quarterly Net profit$27.63 M79.56%negative

Quarterly Net profit fell 79.56% YoY to $27.63 M. Its sector's average net profit growth YoY for the quarter was -50.01%.

Debt to Equity Ratio2.61-negative

Debt to Equity Ratio of 2.61 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE)-49.33 %-49.33%negative

Return on Equity(ROE) for the last financial year was -49.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding14.41 %0.91%positive

Mutual Fund Holding increased by 0.91% in the last quarter to 14.41.

Promoter Share Holding30.52 %6.57%positive

Promoter Share Holding increased by 6.57% in the most recent quarter to 30.52%.

Interest Coverage Ratio-1.79-negative

Interest Coverage Ratio is -1.79, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding29.70 %0%neutral

Institutional Holding remained the same in the last quarter at 29.7%.

VIEW LESS


Loading data..

Inotiv Inc - Company Profile

What does Inotiv Inc do?

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Inotiv Inc Management structure

All Gross Remunerations are in USD
Mr. Robert W. Leasure, Jr
Director, President and Chief Executive Officer
1.66 M
2024
Gross Remuneration
Year
Ms. Beth A. Taylor
Senior Vice President, Finance and Chief Financial Officer
483.71 K
2024
Gross Remuneration
Year
Dr. John E. Sagartz, D.V.M.,PhD
Director and Chief Strategy Officer
474.75 K
2024
Gross Remuneration
Year
Mr. John Gregory Beattie
Chief Operating Officer
-
2024
Gross Remuneration
Year
Dr. Adrian Hardy, PhD
Executive Vice President
-
2024
Gross Remuneration
Year
Mr. Michael Garrett
Chief Commercial Officer
-
2024
Gross Remuneration
Year

Inotiv Inc Board of directors

All Gross Remunerations are in USD
Ms. Terry Coelho
Independent Director
155.42 K
2024
Gross Remuneration
Year
Mr. R. Matthew Neff
Non-Executive Chairman of The Board
146.78 K
2024
Gross Remuneration
Year
Dr. Nigel Brown, PhD
Independent Director
121.78 K
2024
Gross Remuneration
Year
Mr. David Landman
Independent Director
114.28 K
2024
Gross Remuneration
Year
Dr. Gregory C. Davis, PhD
Chairman of the Board
104.29 K
2024
Gross Remuneration
Year
Mr. Michael J. Harrington
Independent Director
89.42 K
2024
Gross Remuneration
Year

Inotiv Inc FAQ

How is Inotiv Inc today?
Inotiv Inc today is trading in the green, and is up by 5.45% at 2.90.
Inotiv Inc is currently trading up 5.45% on an intraday basis. In the past week the stock fell -2.68%. stock has been down -26.40% in the past quarter and fell -72.74% in the past year. You can view this in the overview section.